Trials in Pennsylvania.
120 APOE4-relevant Alzheimer’s trials run in Pennsylvania — 44 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Non-carriers only, not for APOE4NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
- Drug trial for diagnosed APOE4 carriersNCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
- Open to carriers, not 4-specificNCT01482351Mild Cognitive Impairment and Obstructive Sleep Apnea
This study looked at whether sticking with CPAP, the mask-and-airflow machine for sleep apnea, is linked to memory, thinking, and daily function after one year…
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- APOE4/4 only, closed to new enrolleesNCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
- Drug trial for symptomatic early Alzheimer'sNCT06335173A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…
- 4/4 carriers excluded, one copy may qualifyNCT07688213A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing SAR448851, a once-daily oral pill, in people with early Alzheimer's disease who have confirmed amyloid buildup in the brain.…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Drug trial, genotype not specified in sourceNCT00667810Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…
- Drug trial, not APOE4-specific, carriers at riskNCT00676143Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…
- Rare inherited mutation families, not APOE4NCT00869817Dominantly Inherited Alzheimer Network (DIAN)
This is an observational study, meaning no drug or treatment is given. Researchers follow families with a rare inherited gene mutation that causes Alzheimer's,…
- Drug extension study, prior participants onlyNCT00998764A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
This trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…
- Cancer trial, not for healthy carriersNCT01227954Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
This trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…
- Huntington's study, not about APOE4NCT01574053Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…
- Not for APOE4 carriers; mutation carriers onlyNCT01760005Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
This trial tests several investigational drugs, including gantenerumab, solanezumab, E2814 and lecanemab, against placebo. It asks whether they slow cognitive…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Not Alzheimer's-focused, not APOE4-specificNCT02327845Phenotype, Genotype & Biomarkers in ALS and Related Disorders
This is an observational study, so nothing is being tested as a treatment. Researchers are looking at how the genes and symptoms of ALS and related conditions,…
- Observational depression study, not APOE4-specificNCT02434393Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
This observational study follows older adults with late life depression to understand why some develop memory and thinking problems faster. Participants get…
- Lymphoma study, not Alzheimer's-relatedNCT02633111DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
This study looks at whether a blood test can spot aggressive B-cell lymphoma coming back after first-round chemotherapy. The test reads tumor DNA left in the…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Unrelated to APOE4 or Alzheimer'sNCT03047369The Myelin Disorders Biorepository Project
This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Open to carriers, genotype not trackedNCT03113461MCI: CPAP Treatment of OSA (Memories2)
This trial is testing whether CPAP — the device used to treat sleep apnea — can slow the progression of memory problems in people who already have mild…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Open to carriers, not 4-specificNCT03750409Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia
This trial is testing whether a light-emitting helmet that delivers infrared and near-infrared light to the brain can support brain cell activity and…
- Not Alzheimer's-focused, not APOE4-specificNCT03912987TRIAL READY (Clinical Trial Readiness)
This is an observational study, not a drug test. It collects biological fluid samples, such as blood, from people with ALS and related conditions, plus healthy…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Imaging study, genotype not specifiedNCT04251130Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI
This study uses a tau PET scan, with a tracer called PI-2620, to look at tau protein in the brain. Researchers compare those images with high-resolution MRI of…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- Imaging study, genotype not a factorNCT04274998Neuroinflammation Imaging in AD
This early-phase imaging study is testing two radioactive tracers used in PET brain scans to measure neuroinflammation in people with Alzheimer's disease or…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- Wrong condition, not APOE4-relevantNCT04408625Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
This trial is testing LY3884963, a biological therapy delivered directly into the fluid around the brain and spine, in people who have frontotemporal dementia…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Not APOE4-related; FTD gene families onlyNCT04516499Neurofilament Surveillance Project (NSP)
This is a blood-collection study, not a drug test. Researchers are measuring neurofilament, a protein that can signal nerve cell damage, in people from…
- Genotype collected, carriers not excluded yetNCT04639050Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
This Phase 1 trial is testing a drug called RO7126209 — given by IV infusion — in people with early to moderate Alzheimer's who have confirmed amyloid buildup…
- Open to carriers, not 4-specificNCT04715399UPenn Observational Research Repository on Neurodegenerative Disease
This is an observational study at the University of Pennsylvania — no drug or treatment involved. Researchers are building a long-term data repository by…
- Not for APOE4; FTD gene mutations onlyNCT04747431A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
PBFT02 is a gene therapy meant to deliver a working copy of the GRN gene to the brain. This trial looks at its safety, how well people tolerate it, and early…
- Not Alzheimer's-focused, APOE4 not mentionedNCT04875416Phenotype, Genotype and Biomarkers 2
This is an observational study, meaning no drug or treatment is given. Researchers are looking at people with ALS and related conditions, including…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Not Alzheimer-focused, genotype irrelevantNCT04997642Parkinson's Disease and Movement Disorders Clinical Database
This is not a treatment trial. It is a research database at the University of Pennsylvania that collects long-term clinical information, biological samples,…
- Genetic study, carriers likely relevantNCT05010603Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.